Eagle Boston Investment Management Inc. lifted its position in shares of Mednax (NYSE:MD) by 5.1% during the 1st quarter, HoldingsChannel reports. The fund owned 234,123 shares of the company’s stock after buying an additional 11,311 shares during the period. Mednax makes up 1.3% of Eagle Boston Investment Management Inc.’s holdings, making the stock its 19th largest holding. Eagle Boston Investment Management Inc.’s holdings in Mednax were worth $13,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the company. GHP Investment Advisors Inc. boosted its stake in shares of Mednax by 13.8% during the 4th quarter. GHP Investment Advisors Inc. now owns 7,735 shares of the company’s stock worth $413,000 after acquiring an additional 940 shares in the last quarter. Amalgamated Bank lifted its stake in Mednax by 5.9% in the 4th quarter. Amalgamated Bank now owns 18,448 shares of the company’s stock valued at $986,000 after buying an additional 1,035 shares in the last quarter. Macquarie Group Ltd. lifted its stake in Mednax by 36.1% in the 4th quarter. Macquarie Group Ltd. now owns 4,900 shares of the company’s stock valued at $262,000 after buying an additional 1,300 shares in the last quarter. Commerce Bank lifted its stake in Mednax by 9.6% in the 4th quarter. Commerce Bank now owns 15,868 shares of the company’s stock valued at $848,000 after buying an additional 1,393 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in Mednax by 4.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 34,120 shares of the company’s stock valued at $1,823,000 after buying an additional 1,400 shares in the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
Shares of Mednax opened at $47.55 on Friday, according to Marketbeat.com. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market capitalization of $4.43 billion, a price-to-earnings ratio of 15.10, a price-to-earnings-growth ratio of 1.19 and a beta of 0.26. Mednax has a fifty-two week low of $46.83 and a fifty-two week high of $47.15.
Mednax (NYSE:MD) last issued its quarterly earnings results on Monday, April 30th. The company reported $0.89 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.07. The company had revenue of $901.90 million during the quarter, compared to the consensus estimate of $903.75 million. Mednax had a return on equity of 10.13% and a net margin of 9.34%. Mednax’s revenue was up 7.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 EPS. analysts forecast that Mednax will post 3.95 EPS for the current year.
A number of research firms recently issued reports on MD. TheStreet raised Mednax from a “c+” rating to a “b” rating in a research note on Monday, March 12th. Jefferies Group set a $58.00 target price on Mednax and gave the company a “hold” rating in a research note on Thursday, March 15th. Zacks Investment Research lowered Mednax from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 21st. Credit Suisse Group began coverage on Mednax in a research note on Tuesday, March 27th. They issued a “neutral” rating and a $57.00 target price on the stock. Finally, Robert W. Baird upped their target price on Mednax from $48.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, February 9th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $55.92.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total value of $175,050.00. Following the completion of the transaction, the insider now directly owns 39,716 shares in the company, valued at approximately $2,317,428.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.40% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax (NYSE:MD).
Receive News & Ratings for Mednax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax and related companies with MarketBeat.com's FREE daily email newsletter.